Caribou Biosciences, Inc.: management transactions · United States · SEC (Form 4)

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. is a U.S.-listed biotechnology company traded on the NASDAQ under the ticker CRBU. Headquartered in Berkeley, California, the company is a clinical-stage CRISPR genome-editing business focused on developing off-the-shelf cell therapies. Its core technology platform is chRDNA, a proprietary genome-editing approach intended to improve precision in engineered allogeneic cells. The strategic aim is to create therapies that can be manufactured in advance from healthy donor cells, potentially enabling faster treatment, broader access, and better scalability than conventional autologous cell therapy workflows. Caribou was co-founded by pioneers in CRISPR biology, with origins tied to the Doudna lab at the University of California, Berkeley, which gives the company a strong scientific pedigree within the CRISPR ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000036/crbu-20260331.htm?utm_source=openai)) From a historical perspective, Caribou initially built a broader CRISPR technology story but has increasingly concentrated capital and management attention on oncology. The company has explicitly prioritized its pipeline around two lead clinical assets: vispa-cel, formerly CB-010, an allogeneic anti-CD19 CAR-T therapy being developed for relapsed or refractory B-cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T candidate for relapsed or refractory multiple myeloma. These programs sit at the center of Caribou’s investment case, as management seeks to demonstrate clinically meaningful activity and durability while preserving the convenience and manufacturing advantages of an off-the-shelf product concept. ([cariboubio.com](https://www.cariboubio.com/pipeline/?trk=organization-update_share-update_update-text&utm_source=openai)) In competitive terms, Caribou operates in a crowded and scientifically demanding field that includes larger oncology and gene-editing players. Its differentiation is based on the chRDNA editing platform, an allogeneic development strategy, and the clinical signals already generated by its lead programs. The company positions vispa-cel and CB-011 as potentially best-in-class or at least highly differentiated therapies that could reduce turnaround times and expand access for patients with severe hematologic malignancies. At the same time, Caribou remains a development-stage company with no material commercial product revenue, so its valuation is highly dependent on clinical execution, regulatory progress, and financing discipline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000036/crbu-20260331.htm?utm_source=openai)) Recent milestones have been important. In 2025, Caribou reported positive data for vispa-cel from the ANTLER phase 1 trial and encouraging clinical data for CB-011 in multiple myeloma, which helped reinforce confidence in both lead programs. More recently, in March 2026, the company announced that the FDA granted RMAT designation to CB-011 for relapsed or refractory multiple myeloma, a regulatory milestone that may support development momentum. As a NASDAQ-listed U.S. biotech small cap, CRBU offers a high-risk, high-upside exposure to CRISPR-based cell therapy innovation, with clinical readouts and regulatory interactions likely to remain the key drivers. ([investor.cariboubio.com](https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-reports-third-quarter-2025-financial-results?utm_source=openai))